2018 Mar;30(3)
Neal B, Perkovic V, Mahaffey KW, et al
Eligible Part D enrollees can access Wegovy and Zepbound with a prescriber's prior authorization
There is also a trial specifically testing whether retatrutide prevents heart attacks and strokes (TRIUMPH-3, 1,800 people), and a head-to-head trial comparing retatrutide directly against tirzepatide (the active ingredient in Zepbound) under identical conditions (NCT06662383, 800 patients)
Businesses must forecast adoption and have marketing, education, and distribution strategies
Exploring SGLT2 Inhibitors SGLT2 inhibitors, including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana), offer a different therapeutic pathway